Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894851 | 0.79 | APLNR (0.45) | APLNR | |
| SCHEMBL25209623 | 0.79 | APLNR (0.45) | APLNR | |
| SCHEMBL18681799 | 0.76 | SMN1; SMN2 (0.45) | PYCR1APLNRSLC6A4 | |
| SCHEMBL18681951 | 0.76 | SMN1; SMN2 (0.45) | PYCR1APLNRSLC6A4 | |
| SCHEMBL20629700 | 0.76 | SMN1; SMN2 (0.45) | PYCR1APLNRSLC6A4 | |
| SCHEMBL13149137 | 0.75 | IDO1 (0.39) | UCHL1GLANPSR1SLC6A4 | |
| SCHEMBL28686206 | 0.72 | CA1 (0.37) | NPSR1 | |
| SCHEMBL22894691 | 0.71 | PYCR1 (0.49) | PYCR1APLNRNPSR1SLC6A4 | |
| SCHEMBL21700329 | 0.65 | SMN1; SMN2 (0.43) | PYCR1APLNRSLC6A4 | |
| SCHEMBL21761386 | 0.64 | SMN1; SMN2 (0.42) | PYCR1APLNRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088894-A1 | MACROCYCLIC 2-AMINO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-25 | — | — | WO | disclosed |
| WO-2021005043-A1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | WO | disclosed |